Ocular Therapeutix Inc (OCUL) Inventory Turnover Ratio, from second quarter 2026 to second quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Ocular Therapeutix Inc   (NASDAQ: OCUL)
 

Ocular Therapeutix Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the second quarter 2026, Ocular Therapeutix Inc 's inventory turnover ratio sequentially decreased to 1.84 in the second quarter 2026, unsurprisingly, as the Ocular Therapeutix Inc markets continue to deteriorate, and OCUL's faces growing challenges to bring down its inventories. Ocular Therapeutix Inc 's average inventory processing period in the Jun 30 2026 quarter, has increased to 198 days, from 190 days, in the Mar 31 2026 quarter.

Within Healthcare sector 223 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 937 in the first quarter 2026, to 1607.

OCUL Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Ocular Therapeutix Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OCUL Inventory Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Inventory Growth 25.9 % 14.32 % 17.24 % 45.03 % 19.32 %
Y / Y Cost of Sales Growth 3.45 % 5.31 % 29.59 % 13.65 % 28.83 %
Inventory Turnover Ratio (TTM) 1.84 1.92 1.97 1.94 2.04
OCUL's Total Ranking # 1607 # 937 # 426 # 993 # 1171
Average inventory processing period 199 190 185 189 179
Seq. Inventory Growth 2.38 % 4.85 % 2.18 % 14.77 % -7.04 %
Seq. Cost of Sales Growth 51.32 % -16.62 % -10.15 % -8.74 % 54.04 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 64
Healthcare Sector # 224
Overall Market # 1607

Inventory Turnover Ratio Statistics
High Average Low
4.42 2.86 1.84
(Sep 30 2017)   (Jun 30 2026)



OCUL Company Profile >> Back to OCUL Efficiency Comparisons >> Compare OCUL Inventory Turnover Ratio to its Competitors

Financial Statements
Ocular Therapeutix Inc 's Inventories $ 4 Millions Visit OCUL's Balance sheet
Ocular Therapeutix Inc 's Cost of Revenues TTM $ 7 Millions Visit OCUL's Income Statement
What are OCUL's Sales? Visit OCUL's Sales by Segment

Other Inventory Turnover Ratios
Ocular Therapeutix Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
OCUL's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for OCUL's Competitors
Inventory Turnover Ratio for OCUL's Suppliers
Inventory Turnover Ratio for OCUL's Customers

You may also want to know
OCUL's Sales Growth Rates OCUL's Pe Price to earnings ratio OCUL's Receivables Turnover Ratio OCUL's Stock Quote
OCUL's Net Income Growth Rates OCUL's Ps Price to Sales ratio OCUL's Sales per Employee OCUL's Asset Turnover Ratio
OCUL's Net Margin OCUL's Pb Price to Book ratio OCUL's Financial Strength Ratios OCUL's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Jun 30 2026 Inventories at quarter ending Jun 30 2026
West Pharmaceutical Services Inc   4.72 $ 2,103.100  Millions$ 445  Millions
Henry Schein Inc   4.68 $ 9,342.000  Millions$ 1,997  Millions
Guardant Health Inc   4.53 $ 413.947  Millions$ 91  Millions
Integrated Biopharma Inc  4.50 $ 41.768  Millions$ 9  Millions
Idexx Laboratories Inc  4.44 $ 1,714.440  Millions$ 386  Millions
Cryoport inc   4.40 $ 98.679  Millions$ 22  Millions
Envista Holdings Corporation  4.37 $ 1,278.500  Millions$ 293  Millions
Vericel Corporation  4.30 $ 77.922  Millions$ 18  Millions
Myomo Inc   4.23 $ 14.262  Millions$ 3  Millions
Adc Therapeutics Sa  4.17 $ 5.806  Millions$ 1  Millions
Scilex Holding Company  4.08 $ 14.867  Millions$ 4  Millions
Medinotec Inc   4.08 $ 4.736  Millions$ 1  Millions
Alpha Teknova Inc   4.08 $ 28.288  Millions$ 7  Millions
3m Company  4.07 $ 15,258.000  Millions$ 3,754  Millions
Coherus Oncology inc   4.03 $ 15.822  Millions$ 4  Millions
Electromed Inc   4.02 $ 14.133  Millions$ 4  Millions
Novocure Limited  4.02 $ 166.921  Millions$ 41  Millions
Koru Medical Systems Inc   3.97 $ 16.948  Millions$ 4  Millions
Elite Pharmaceuticals Inc   3.95 $ 78.824  Millions$ 20  Millions
Escalon Medical Corp   3.94 $ 7.167  Millions$ 2  Millions
Lftd Partners Inc   3.89 $ 29.233  Millions$ 8  Millions
Pmgc Holdings Inc   3.87 $ 1.364  Millions$ 0  Millions
Sonoma Pharmaceuticals Inc   3.83 $ 13.392  Millions$ 3  Millions
Intelligent Bio Solutions Inc   3.80 $ 2.165  Millions$ 1  Millions
Iridex Corp  3.80 $ 32.517  Millions$ 9  Millions
Biocryst Pharmaceuticals Inc   3.69 $ 20.926  Millions$ 6  Millions
Abbvie Inc   3.66 $ 18,365.000  Millions$ 5,016  Millions
Teva Pharmaceutical Industries Limited  3.66 $ 8,232.000  Millions$ 2,250  Millions
Neuraxis Inc   3.55 $ 0.783  Millions$ 0  Millions
Beyond Air Inc   3.51 $ 6.447  Millions$ 2  Millions

Date modified: 2026-10-05T11:03:41+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.